Sofie Demeyer

Sofie Demeyer

Auto-generated profile, based on publicly available information

Sofie Demeyer

Laboratory for Molecular Biology of Leukemia, VIB-KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MRMatteo Rossi
Matteo Rossi
PAPatricia Altea-Manzano
Patricia Altea-Manzano
MDMargherita Demicco
Margherita Demicco
GDGinevra Doglioni
Ginevra Doglioni
LBLaura Bornes
Laura Bornes
SFSarah-Maria Fendt
Sarah-Maria Fendt

1 December 2008
Verified
Conference Paper
Closed access
MPMario Pickavet
Mario Pickavet
WVWillem Vereecken
Willem Vereecken
SDSofie Demeyer
Sofie Demeyer
PAPieter Audenaert
Pieter Audenaert
BVBrecht Vermeulen
Brecht Vermeulen
PDPiet Demeester
Piet Demeester
As Information and Communication Technology (ICT) is becoming more and more wide-spread and pervasive in our daily life, it is important to get a realistic overview of the worldwide impact of ICT on the environment in general and on energy and electricity needs in particular. This paper reports on a detailed study to estimate this impact today and to predict how this will evolve in the future. From this survey, important conclusions for the future of ICT industry and the Internet will be drawn, and challenges and research directives will be deduced.

23 July 2015 in Haematologica
Verified
Journal Article
Open access
PDF file
CVC. Vicente
C. Vicente
CSC. Schwab
C. Schwab
MBM. Broux
M. Broux
EGE. Geerdens
E. Geerdens
SDS. Degryse
S. Degryse
JCJan Cools
Jan Cools
T-cell acute lymphoblastic leukemia is caused by the accumulation of multiple oncogenic lesions, including chromosomal rearrangements and mutations. To determine the frequency and co-occurrence of mutations in T-cell acute lymphoblastic leukemia, we performed targeted re-sequencing of 115 genes across 155 diagnostic samples (45 adult and 110 childhood cases). NOTCH1 and CDKN2A/B were mutated/deleted in more than half of the cases, while an additional 37 genes were mutated/deleted in 4 to 20% of cases. We identified the IL7R-JAK pathway to be mutated in 27.7% of cases, with JAK3 mutations being the most frequent event in this group. Copy number variations were also detected, including deletions of CREBBP or CTCF and duplication of MYB. FLT3 mutations were rare, but a novel extracellular mutation in FLT3 was detected and confirmed to be transforming. Furthermore, we identified complex patterns of pairwise associations, including a significant association between mutations in IL7R-JAK genes and epigenetic regulators (WT1, PRC2, PHF6). Our analyses showed that IL7R-JAK genetic lesions did not confer adverse prognosis in T-cell acute lymphoblastic leukemia cases enrolled in the UK ALL2003 trial. Overall, these results identify interconnections between the T-cell acute lymphoblastic leukemia genome and disease biology, and suggest a potential clinical application for JAK inhibitors in a significant proportion of T-cell acute lymphoblastic leukemia patients.

13 November 2014 in Blood
Verified
Journal Article
Open access
PDF file
SDSandrine Degryse
Sandrine Degryse
CBCharles E. de Bock
Charles E. de Bock
LCLuk Cox
Luk Cox
SDSofie Demeyer
Sofie Demeyer
OGOlga Gielen
Olga Gielen
JCJan Cools
Jan Cools
JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vitro and in vivo assays. Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOHITO cell lines to cytokine-independent proliferation. JAK3 pseudokinase mutants were dependent on Jak1 kinase activity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak1 kinase–independent manner. Reconstitution of the IL7 receptor signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downstream STAT5 phosphorylation. Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-ALL–like disease, characterized by an accumulation of immature CD8+ T cells. In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis. Our data show that JAK3 mutations are drivers of T-ALL and require the cytokine receptor complex for transformation. These results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

2 February 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
PAPatricia Altea-Manzano
Patricia Altea-Manzano
GDGinevra Doglioni
Ginevra Doglioni
YLYawen Liu
Yawen Liu
ACAlejandro M. Cuadros
Alejandro M. Cuadros
ENEmma Nolan
Emma Nolan
SFSarah-Maria Fendt
Sarah-Maria Fendt
Metabolic rewiring is often considered an adaptive pressure limiting metastasis formation; however, some nutrients available at distant organs may inherently promote metastatic growth. We find that the lung and liver are lipid-rich environments. Moreover, we observe that pre-metastatic niche formation increases palmitate availability only in the lung, whereas a high-fat diet increases it in both organs. In line with this, targeting palmitate processing inhibits breast cancer-derived lung metastasis formation. Mechanistically, breast cancer cells use palmitate to synthesize acetyl-CoA in a carnitine palmitoyltransferase 1a-dependent manner. Concomitantly, lysine acetyltransferase 2a expression is promoted by palmitate, linking the available acetyl-CoA to the acetylation of the nuclear factor-kappaB subunit p65. Deletion of lysine acetyltransferase 2a or carnitine palmitoyltransferase 1a reduces metastasis formation in lean and high-fat diet mice, and lung and liver metastases from patients with breast cancer show coexpression of both proteins. In conclusion, palmitate-rich environments foster metastases growth by increasing p65 acetylation, resulting in a pro-metastatic nuclear factor-kappaB signaling.

29 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RHRoger A. Habets
Roger A. Habets
CBCharles E. de Bock
Charles E. de Bock
LSLutgarde Serneels
Lutgarde Serneels
ILInge Lodewijckx
Inge Lodewijckx
DVDelphine Verbeke
Delphine Verbeke
BSBart De Strooper
Bart De Strooper
Given the high frequency of activating NOTCH1 mutations in T cell acute lymphoblastic leukemia (T-ALL), inhibition of the γ-secretase complex remains an attractive target to prevent ligand-independent release of the cytoplasmic tail and oncogenic NOTCH1 signaling. However, four different γ-secretase complexes exist, and available inhibitors block all complexes equally. As a result, these cause severe “on-target” gastrointestinal tract, skin, and thymus toxicity, limiting their therapeutic application. Here, we demonstrate that genetic deletion or pharmacologic inhibition of the presenilin-1 (PSEN1) subclass of γ-secretase complexes is highly effective in decreasing leukemia while avoiding dose-limiting toxicities. Clinically, T-ALL samples were found to selectively express only PSEN1-containing γ-secretase complexes. The conditional knockout of Psen1 in developing T cells attenuated the development of a mutant NOTCH1-driven leukemia in mice in vivo but did not abrogate normal T cell development. Treatment of T-ALL cell lines with the selective PSEN1 inhibitor MRK-560 effectively decreased mutant NOTCH1 processing and led to cell cycle arrest. These observations were extended to T-ALL patient-derived xenografts in vivo, demonstrating that MRK-560 treatment decreases leukemia burden and increased overall survival without any associated gut toxicity. Therefore, PSEN1-selective compounds provide a potential therapeutic strategy for safe and effective targeting of T-ALL and possibly also for other diseases in which NOTCH signaling plays a role.